[go: up one dir, main page]

SG11201706146UA - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors - Google Patents

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors

Info

Publication number
SG11201706146UA
SG11201706146UA SG11201706146UA SG11201706146UA SG11201706146UA SG 11201706146U A SG11201706146U A SG 11201706146UA SG 11201706146U A SG11201706146U A SG 11201706146UA SG 11201706146U A SG11201706146U A SG 11201706146UA SG 11201706146U A SG11201706146U A SG 11201706146UA
Authority
SG
Singapore
Prior art keywords
amido
bicyclic
alkyl
hdac inhibitors
hydroxamic acids
Prior art date
Application number
SG11201706146UA
Other languages
English (en)
Inventor
Xiaozhang Zheng
Pui Yee Ng
Bingsong Han
Jennifer R Thomason
Mary-Margaret Zablocki
Cuixian Liu
Heather Davis
Aleksandra Rudnitskaya
Jr David Lancia
Kenneth W Bair
David S Millan
Matthew W Martin
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of SG11201706146UA publication Critical patent/SG11201706146UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201706146UA 2015-02-02 2016-02-02 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors SG11201706146UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562110716P 2015-02-02 2015-02-02
US201562205438P 2015-08-14 2015-08-14
PCT/US2016/016201 WO2016126725A1 (en) 2015-02-02 2016-02-02 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors

Publications (1)

Publication Number Publication Date
SG11201706146UA true SG11201706146UA (en) 2017-08-30

Family

ID=55353351

Family Applications (4)

Application Number Title Priority Date Filing Date
SG11201706146UA SG11201706146UA (en) 2015-02-02 2016-02-02 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
SG10202100915RA SG10202100915RA (en) 2015-02-02 2016-02-02 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
SG10202100916PA SG10202100916PA (en) 2015-02-02 2016-02-02 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
SG11201708622UA SG11201708622UA (en) 2015-02-02 2016-02-02 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG10202100915RA SG10202100915RA (en) 2015-02-02 2016-02-02 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
SG10202100916PA SG10202100916PA (en) 2015-02-02 2016-02-02 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
SG11201708622UA SG11201708622UA (en) 2015-02-02 2016-02-02 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors

Country Status (27)

Country Link
US (32) US10112915B2 (zh)
EP (3) EP3292116B8 (zh)
JP (1) JP6668362B2 (zh)
KR (1) KR102633628B1 (zh)
CN (3) CN107873023B (zh)
AU (4) AU2016215431B2 (zh)
BR (1) BR112017016493B1 (zh)
CA (2) CA2990165C (zh)
CL (1) CL2017001968A1 (zh)
CO (1) CO2017007863A2 (zh)
DK (1) DK3292116T3 (zh)
EA (2) EA201792673A1 (zh)
EC (1) ECSP17055491A (zh)
ES (2) ES2770123T3 (zh)
HK (2) HK1251550A1 (zh)
HU (1) HUE057623T2 (zh)
IL (4) IL280856B (zh)
MA (1) MA42032A (zh)
MX (2) MX373137B (zh)
MY (1) MY191591A (zh)
PH (1) PH12017501383B1 (zh)
PL (1) PL3292116T3 (zh)
PT (1) PT3292116T (zh)
SA (1) SA517382027B1 (zh)
SG (4) SG11201706146UA (zh)
TW (6) TW201629026A (zh)
WO (4) WO2016126724A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280856B (en) 2015-02-02 2022-09-01 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
TW201639811A (zh) 2015-03-13 2016-11-16 佛瑪治療公司 作為ＨＤＡＣ８抑制劑之α－桂皮醯胺化合物與組成物
US10029995B2 (en) 2015-09-03 2018-07-24 Forma Therapeutics, Inc. [6,6] fused bicyclic HDAC8 inhibitors
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
TWI794232B (zh) * 2017-05-17 2023-03-01 美商戴納立製藥公司 激酶抑制劑及其用途
US11161825B2 (en) * 2017-08-15 2021-11-02 Bayer Aktiengesellschaft 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides
WO2020096916A2 (en) 2018-11-08 2020-05-14 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
CN111848591B (zh) * 2019-04-25 2022-03-18 成都先导药物开发股份有限公司 Hdac抑制剂及其制备方法和用途
US11453661B2 (en) * 2019-09-27 2022-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN113527206B (zh) * 2020-04-17 2022-12-30 上海中泽医药科技有限公司 一种苯并氮杂环类化合物、其制备方法及用途
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
CN112691706A (zh) * 2020-12-23 2021-04-23 中触媒新材料股份有限公司 一种乙醇制乙腈催化剂的再生方法
IL307883A (en) 2021-04-23 2023-12-01 Tenaya Therapeutics Inc HDAC6 inhibitors for use in the treatment of dilated myocardial disease
IL308152A (en) 2021-05-04 2024-01-01 Tenaya Therapeutics Inc 2-fluoroalkyl-4,3,1-oxadiazol-5-yl-thiazole, HDAC6 inhibitors for use in the treatment of metabolic disease and HFPEF
TWI829329B (zh) * 2021-09-06 2024-01-11 臺北醫學大學 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
WO2023081328A1 (en) * 2021-11-04 2023-05-11 Valo Health, Inc. Histone deacetylase 6 inhibitor compounds and uses thereof
WO2024104823A1 (en) 2022-11-16 2024-05-23 Basf Se New substituted tetrahydrobenzoxazepine
WO2024104822A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted tetrahydrobenzodiazepine as fungicides
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557425C2 (de) 1975-12-19 1987-03-19 C.H. Boehringer Sohn, 6507 Ingelheim 11-Oxo-11-H-pyrido[2,1-b]-chinazolin-2-carbonsäure und ihre Salze, Verfahren zu ihrer Herstellung und Arzneimittel
DE3704203A1 (de) 1987-02-11 1988-08-25 Boehringer Ingelheim Kg Verwendung von oxochinazolinderivaten bei der behandlung der hyperurikaemie
US5244911A (en) 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
US5153185A (en) 1991-04-16 1992-10-06 Merck & Co., Inc. 2-phenanthridonyl carbapenems
US5294610A (en) 1992-10-15 1994-03-15 Merck & Co. Inc. 2-(aza-9-fluorenonyl)carbapenem antibacterial agents
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP0638071B1 (en) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
EP0695184B1 (en) 1993-01-15 1999-04-21 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
US5384317A (en) 1993-08-02 1995-01-24 Merck & Co., Inc. Bridged biphenyl carbapenem compounds, compositions containing such compounds and methods of use
US6872542B1 (en) 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
JPH09505309A (ja) 1993-11-18 1997-05-27 ワシントン・ユニバーシティ 細菌感染の治療および予防のための化合物および医薬組成物
US6110913A (en) 1994-01-04 2000-08-29 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US5532261A (en) 1994-12-12 1996-07-02 Merck & Co., Inc. Carbapenem antibiotics, compositions containing such compounds and methods of use
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2201477C (en) 1995-08-02 2005-05-03 Javier Bartroli New pyrimidone derivatives with antifungal activity
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
WO1997048786A1 (de) 1996-06-19 1997-12-24 Call Hans Peter Mehrkomponentensystem zur verwendung mit waschaktiven substanzen
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
DE19726241A1 (de) 1997-06-20 1998-12-24 Call Krimhild Erweitertes enzymatisches Multikomponentensystem zur Behandlung von Abwässern, zur Herstellung von Holzverbundstoffen, zum Deinken von Altpapier, Colour stripping von Altpapier, zum Einsatz als Oxidationssystem bei der organischen Synthese und zum Einsatz bei der Kohleverflüssigung
IL121748A0 (en) 1997-09-11 1998-02-22 Yeda Res & Dev Vanadium complexes of hydroxamates and pharmaceutical compositions comprising them
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6180640B1 (en) 1998-06-25 2001-01-30 Sepracor, Inc. Di- and tetra-hydroquinoline-indole antimicrobial agents, uses and compositions related thereto
JP2000044562A (ja) 1998-07-31 2000-02-15 Kyowa Hakko Kogyo Co Ltd ピロロフタルイミド誘導体
US6288099B1 (en) 1998-12-04 2001-09-11 American Home Products Corporation Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
EP1135393A2 (en) 1998-12-04 2001-09-26 American Home Products Corporation Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
JP2000357809A (ja) 1999-06-15 2000-12-26 Fuji Photo Film Co Ltd 光電変換材料、光電変換素子及びポリメチン色素
JP4162106B2 (ja) 1999-06-17 2008-10-08 富士フイルム株式会社 光電変換素子および光電気化学電池ならびに金属錯体色素
AU6525300A (en) 1999-08-13 2001-03-13 Sepracor, Inc. Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
FR2809391B1 (fr) 2000-05-29 2003-05-09 Rhodia Chimie Sa Nouveau mortier phosphomagnesien, procede d'obtention de ce mortier
ES2572332T3 (es) 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
AU2002214222A1 (en) 2000-11-01 2002-05-15 Yeda Research And Development Co..Ltd. Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia
JP2004514669A (ja) 2000-11-07 2004-05-20 ブリストル−マイヤーズ　スクイブ　カンパニー セリンプロテアーゼ阻害剤として有用な酸誘導体
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
IN192526B (zh) 2001-09-25 2004-04-24 Ranbaxy Lab
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
DE60320957D1 (en) 2002-03-13 2008-06-26 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase-inhibitoren
WO2003087059A2 (en) 2002-04-08 2003-10-23 Sun Pharmaceutical Industries Limited (e)-oxime ether derivative of 5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
BR0317528A (pt) 2002-12-20 2005-11-22 Basf Ag Uso dos compostos, métodos para o controle de insetos, aracnìdeos ou nematodos, e para a proteção de plantas em crescimento contra o ataque ou a infestação por insetos, aracnìdeos ou nematodos, compostos, e, composições
JP2004210716A (ja) 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
WO2004063156A1 (en) 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
WO2004096139A2 (en) 2003-04-24 2004-11-11 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
GB0313766D0 (en) 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
US8227636B2 (en) * 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
US7705017B2 (en) 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
CN1953982B (zh) 2004-05-17 2011-07-06 泰博特克药品有限公司 4-取代-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮
WO2005121139A1 (en) 2004-06-09 2005-12-22 Altana Pharma Ag Substituted tricyclic benzimidazoles
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
AR051041A1 (es) 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
UY29198A1 (es) 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
WO2006065842A2 (en) 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
CA2596355C (en) 2005-01-31 2015-01-06 Ception Therapeutics, Inc. Tumor necrosis factor inhibitors
EP3354265A1 (en) 2005-03-22 2018-08-01 President and Fellows of Harvard College Treatment of solid tumors
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
AR057061A1 (es) 2005-06-16 2007-11-14 Altana Pharma Ag Espiro-bencimidazoles farmaceuticamente activos y su uso en la fabricacion de medicamentos
JP2008543867A (ja) 2005-06-17 2008-12-04 ワイス セロトニン阻害剤ならびに５−ｈｔ１ａアゴニストおよびアンタゴニストとして有用な三環系化合物
EP1904454A2 (en) 2005-06-22 2008-04-02 Nycomed GmbH Process for the production of intermadiates for the preparation of tricyclic benzimidazoles
US7456195B2 (en) 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
CA2619518A1 (en) 2005-08-22 2007-03-01 Nycomed Gmbh Isotopically substituted benzimidazole derivatives
EP1940805A4 (en) 2005-08-26 2009-11-11 Methylgene Inc BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
US8518964B2 (en) 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
CA2632444A1 (en) 2005-12-19 2007-06-28 Boehringer Ingelheim International Gmbh Use of aminoalcohol derivatives for the treatment of overactive bladder
DE102005061655A1 (de) 2005-12-22 2007-06-28 Merck Patent Gmbh Diazepinone
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP1991247B1 (en) 2006-02-14 2015-10-14 President and Fellows of Harvard College Bifunctional histone deacetylase inhibitors
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US8338416B2 (en) 2006-03-16 2012-12-25 Pharmacylics, Inc. Indole derivatives as inhibitors of histone deacetylase
WO2007115409A1 (en) 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP2035042A2 (en) 2006-06-12 2009-03-18 Viamet Pharmaceuticals, Inc. Metallo-hydrolase inhibitors using metal binding moieties in combination with targeting moieties
US20070293530A1 (en) 2006-06-14 2007-12-20 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
CN101108859A (zh) 2006-07-17 2008-01-23 上海恒瑞医药有限公司 长春碱类化合物、其制备方法及其在医药上的用途
CN101495186A (zh) 2006-07-26 2009-07-29 诺瓦提斯公司 十一异戊二烯基焦磷酸酯合酶的抑制剂
US20100173332A1 (en) 2006-09-07 2010-07-08 Auckland Uniservices Limited Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
WO2008048648A2 (en) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
WO2008046155A1 (en) 2006-10-20 2008-04-24 Dia-B Tech Limited Methods for regulating glucose homeostasis and agents therefor
CN105481788A (zh) 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2008053131A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
WO2008061160A1 (en) 2006-11-14 2008-05-22 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
US7820711B2 (en) 2006-11-14 2010-10-26 Pharmacyclics Inc. Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders
US7951795B2 (en) 2006-12-08 2011-05-31 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as CGRP receptor antagonists
WO2008071765A1 (en) 2006-12-14 2008-06-19 Nycomed Gmbh Pharmaceutically active spiro-substituted benzimidazole derivatives
WO2008074858A1 (en) 2006-12-21 2008-06-26 Nycomed Gmbh Intermediates and process for the production of 5-substituted tricyclic benzimidazoles
BRPI0806447A2 (pt) 2007-02-09 2011-09-06 Forest Laboratoires Holdings Ltd formulação de compostos heterocìclicos, método para tratar condição inflamatória ou alérgica e forma amorfa sustancialmente pura de um composto
WO2008101186A1 (en) 2007-02-15 2008-08-21 The J. David Gladstone Institutes Inhibitors for hdac8
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
US20090105283A1 (en) 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
MX2009012847A (es) 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
WO2009015208A1 (en) 2007-07-23 2009-01-29 Replidyne, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
ES2403284T3 (es) 2008-01-09 2013-05-17 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de la proteína quinasa AKT
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
EP2244709A4 (en) 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
JP2009191041A (ja) 2008-02-18 2009-08-27 Univ Of Tokyo ヒドロキシメチルケトン誘導体
EP2100879A1 (en) 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US8980877B2 (en) 2008-04-15 2015-03-17 Dac S.R.L. Spirocyclic derivatives as histone deacetylase inhibitors
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
EP2311840A1 (en) 2009-10-13 2011-04-20 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009137503A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
WO2009137492A1 (en) 2008-05-05 2009-11-12 Abbott Laboratories Heteroaryl-fused macrocyclic pyrimidine derivatives
US8058427B2 (en) 2008-06-12 2011-11-15 National Health Research Institutes Coumarin compounds and their use for treating cancer
EP2303888B1 (en) 2008-06-12 2015-05-06 President and Fellows of Harvard College Compounds for antimicrobial intervention
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
AU2009291602B2 (en) 2008-09-11 2013-02-14 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
AR073630A1 (es) 2008-10-07 2010-11-17 Schering Corp Analogos de espiroaminooxazolina como moduladores de los receptores adrenergicos alfa2c
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
ES2565611T3 (es) 2008-10-14 2016-04-05 Entasis Therapeutics Limited Compuestos heteroaromáticos espirocíclicos y condensados para el tratamiento de infecciones bacterianas
CA2740389A1 (en) 2008-10-15 2010-05-20 Gilead Sciences, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2355825A2 (en) 2008-11-10 2011-08-17 Schering Corporation Compounds for the treatment of inflammatory disorders
RU2470934C1 (ru) 2008-11-11 2012-12-27 Дзе Ил Фармасьютикал Ко., Лтд. Новое трициклическое производное или его фармацевтически приемлемые соли, способ их получения и содержащая их фармацевтическая композиция
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
CN109651342A (zh) 2009-03-27 2019-04-19 默沙东公司 丙型肝炎病毒复制的抑制剂
CA2758149A1 (en) 2009-04-09 2010-10-14 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
WO2010125469A1 (en) 2009-04-29 2010-11-04 Glenmark Pharmaceuticals, S.A. Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators
WO2010151317A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JP5798115B2 (ja) * 2009-06-22 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 置換ヒドロキサム酸およびその使用
AU2010263113B2 (en) 2009-06-23 2015-11-26 Translational Drug Development, Llc Benzamide derivatives
EP2266985A1 (en) 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
ES2736200T3 (es) 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
IN2012DN03217A (zh) 2009-09-16 2015-10-23 Cylene Pharmaceuticals Inc
MY184074A (en) 2009-09-28 2021-03-17 Hoffmann La Roche Benzoxazepin p13k inhibitors compounds and methods of use
KR20140034948A (ko) 2009-09-28 2014-03-20 에프. 호프만-라 로슈 아게 벤즈옥세핀 ｐｉ3ｋ 억제제 화합물 및 사용 방법
EP2305643A1 (en) 2009-10-02 2011-04-06 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
US9221773B2 (en) 2009-12-22 2015-12-29 The Translational Genomics Research Institute Benzamide derivatives
US8198290B2 (en) 2009-12-23 2012-06-12 Berry And Associates, Inc. Methoxatin derivatives
WO2011084991A2 (en) 2010-01-08 2011-07-14 President And Fellows Of Harvard College Fluorinated hdac inhibitors and uses thereof
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
JP2011148714A (ja) 2010-01-19 2011-08-04 Nippon Soda Co Ltd 病害防除方法
EA026514B1 (ru) 2010-01-22 2017-04-28 Эситайлон Фармасьютикалз Инк. Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2011106632A1 (en) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8546588B2 (en) 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8946223B2 (en) 2010-04-12 2015-02-03 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2012012322A1 (en) 2010-07-19 2012-01-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20120015942A1 (en) 2010-07-19 2012-01-19 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20130210899A1 (en) 2010-07-30 2013-08-15 The Regents Of The University Of California Method and Therapeutic for the Treatment and Regulation of Memory Formation
WO2012027564A1 (en) 2010-08-26 2012-03-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012031993A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Novel n-hydroxy-benzamides for the treatment of cancer
AU2011311531B2 (en) 2010-10-08 2014-11-20 Life Sciences Research Partners Vzw HDAC inhibitors to treat Charcot-Marie-Tooth disease
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
AU2011319685B2 (en) 2010-10-22 2016-02-04 Le Centre National De La Recherche Scientifique Pochoxime conjugates useful for the treatment of HSP90 related pathologies
JP6041808B2 (ja) 2010-11-16 2016-12-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 蛋白質脱アセチル化酵素抑制剤としてのピリミジン水酸基アミド化合物およびその利用方法
CN102558200A (zh) 2010-12-21 2012-07-11 复旦大学 长春碱类衍生物、其制备方法及其在医药上的用途
WO2012088015A2 (en) 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012085003A1 (en) 2010-12-22 2012-06-28 Katholieke Universiteit Leuven, K.U. Leuven R&D 2-hydroxyisoquinoline-1,3(2h,4h)-diones and related compounds useful as hiv replication inhibitors
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
US9029391B2 (en) 2011-01-24 2015-05-12 Viiv Healthcare Uk Limited Isoquinoline compounds and methods for treating HIV
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2012112525A1 (en) 2011-02-14 2012-08-23 Alkermes, Inc. PERIPHERIALLY ACTING μ OPIOID ANTAGONISTS
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012110860A1 (en) 2011-02-17 2012-08-23 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2012117421A1 (en) 2011-03-02 2012-09-07 Orchid Research Laboratories Ltd Histone deacetylase inhibitors
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
CN102838625B (zh) 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
EP2723338A2 (en) 2011-06-24 2014-04-30 The Trustees of Stevens Institute of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
JP6047563B2 (ja) 2011-07-08 2016-12-21 ノバルティス アーゲー 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の治療におけるその使用
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
EP2763531A4 (en) 2011-10-03 2015-11-18 Univ Columbia NEW MOLECULES FOR THE SELECTIVE INHIBITION OF HISTONDEACETYLASE 6 IN RELATION TO HISTONDEACETYLASE 1
JP6224600B2 (ja) 2011-10-18 2017-11-01 エコール ポリテクニーク フェデラル ドゥ ローザンヌ（エーペーエフエル） 電気化学および／または光電子デバイス用化合物
WO2013059582A2 (en) 2011-10-20 2013-04-25 Nupotential, Inc. Small molecule inhibitors of histone deacteylases
ES2671387T3 (es) 2011-12-11 2018-06-06 Viamet Pharmaceuticals (NC), Inc. Compuestos inhibidores de metaloenzimas
EA030609B8 (ru) 2011-12-15 2018-10-31 Алкермес Фарма Айэленд Лимитед Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
WO2013134467A1 (en) 2012-03-07 2013-09-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
GB2503789A (en) 2012-05-15 2014-01-08 Syngenta Participations Ag Quinazoline derivatives as antifungal agents
EP2872474B1 (en) 2012-07-10 2022-01-19 Georgia State University Research Foundation, Inc. Anthraquinone analogs and methods of making and using thereof
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014018919A1 (en) 2012-07-27 2014-01-30 The Regents Of The University Of California Seriniquinones, melanoma-specific anticancer agents
BR112015004648A2 (pt) 2012-09-05 2017-07-04 Bayer Cropscience Ag amidas de ácidos bicicloaril carboxílicos com atividade herbicida
ES2625959T3 (es) 2012-09-28 2017-07-21 Bayer Pharma Aktiengesellschaft 5-Aril-triazolo-azepinas inhibidoras de la proteína BET
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6321685B2 (ja) 2013-02-25 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
MY184756A (en) 2013-04-29 2021-04-20 Chong Kun Dang Pharmaceutical Corp Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
JP6353032B2 (ja) 2013-04-30 2018-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジアミノピラジン化合物、前記化合物を含有する医薬、その使用、およびその調製方法
US9278963B2 (en) 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
RU2660897C2 (ru) 2014-03-12 2018-07-11 Чонг Кун Данг Фармасьютикал Корп. Новые соединения в качестве ингибиторов гистондеацетилазы 6 и содержащие их фармацевтические композиции
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
IL280856B (en) 2015-02-02 2022-09-01 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
GB201505133D0 (en) * 2015-03-26 2015-05-06 Egerton Charles E And Scott Harden Simon Self-propelled water board apparatus
WO2016168660A1 (en) 2015-04-17 2016-10-20 Forma Therapeutics, Inc. 3-spiro-7-hydroxamic acid tetralins as hdac inhibitors
FI3362445T3 (fi) 2015-10-12 2023-03-21 Chong Kun Dang Pharmaceutical Corp Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors

Also Published As

Publication number Publication date
US10494354B2 (en) 2019-12-03
US20160221972A1 (en) 2016-08-04
US10479772B2 (en) 2019-11-19
US10829462B2 (en) 2020-11-10
TWI768557B (zh) 2022-06-21
MY191591A (en) 2022-06-30
PL3292116T3 (pl) 2022-02-21
US10112915B2 (en) 2018-10-30
TW201629026A (zh) 2016-08-16
US20160221973A1 (en) 2016-08-04
US20190119235A1 (en) 2019-04-25
CO2017007863A2 (es) 2017-10-20
IL255111A (en) 2018-02-28
BR112017016493A2 (pt) 2018-04-10
EP3292116B8 (en) 2021-11-24
CN107801396B (zh) 2021-10-22
US10414738B2 (en) 2019-09-17
IL253652B (en) 2021-03-25
WO2016126724A1 (en) 2016-08-11
US20220363651A1 (en) 2022-11-17
US10457652B2 (en) 2019-10-29
JP2018503674A (ja) 2018-02-08
SG11201708622UA (en) 2017-11-29
US20210009540A1 (en) 2021-01-14
SA517382027B1 (ar) 2021-06-15
AU2016215432B2 (en) 2020-07-30
US10421731B2 (en) 2019-09-24
US10472337B2 (en) 2019-11-12
ES2770123T3 (es) 2020-06-30
IL279830A (en) 2021-01-31
MA42032A (fr) 2018-03-14
US10214500B2 (en) 2019-02-26
DK3292116T3 (da) 2022-01-10
CN114057765A (zh) 2022-02-18
TW202136220A (zh) 2021-10-01
KR102633628B1 (ko) 2024-02-02
US20220204461A1 (en) 2022-06-30
AU2016215432A1 (en) 2017-08-17
WO2016126725A1 (en) 2016-08-11
TWI776156B (zh) 2022-09-01
US10214501B2 (en) 2019-02-26
SG10202100915RA (en) 2021-02-25
US10494353B2 (en) 2019-12-03
CL2017001968A1 (es) 2018-04-13
US20190112283A1 (en) 2019-04-18
US10988450B2 (en) 2021-04-27
CA2990165A1 (en) 2016-08-11
WO2016126722A1 (en) 2016-08-11
IL280856B (en) 2022-09-01
US10239845B2 (en) 2019-03-26
US20190119232A1 (en) 2019-04-25
US10494351B2 (en) 2019-12-03
US11891365B2 (en) 2024-02-06
US10501424B2 (en) 2019-12-10
MX2017009950A (es) 2017-11-23
US20190119233A1 (en) 2019-04-25
AU2016215431B2 (en) 2020-07-23
BR112017016493B1 (pt) 2023-12-12
IL255111B (en) 2021-01-31
PT3292116T (pt) 2022-01-14
US20190112284A1 (en) 2019-04-18
TW201636334A (zh) 2016-10-16
US10464909B2 (en) 2019-11-05
US10513501B2 (en) 2019-12-24
US20190112282A1 (en) 2019-04-18
PH12017501383A1 (en) 2018-01-08
US20190119231A1 (en) 2019-04-25
EP4015514A1 (en) 2022-06-22
IL253652A0 (en) 2017-09-28
US10428031B2 (en) 2019-10-01
CA2990165C (en) 2023-12-12
US20200055830A1 (en) 2020-02-20
US20190119234A1 (en) 2019-04-25
US20190119230A1 (en) 2019-04-25
US20200048211A1 (en) 2020-02-13
US20190119228A1 (en) 2019-04-25
US11279681B2 (en) 2022-03-22
US20200048212A1 (en) 2020-02-13
US20210009538A1 (en) 2021-01-14
EA201791747A1 (ru) 2018-01-31
MX373137B (es) 2020-04-20
KR20170122759A (ko) 2017-11-06
US20190016692A1 (en) 2019-01-17
US10421732B2 (en) 2019-09-24
US10377726B2 (en) 2019-08-13
CA2975605C (en) 2023-12-12
PH12017501383B1 (en) 2022-05-04
AU2016215431A1 (en) 2018-01-18
US11274084B2 (en) 2022-03-15
MX2020003488A (es) 2022-05-24
CN107801396A (zh) 2018-03-13
CN107873023A (zh) 2018-04-03
TW201643145A (zh) 2016-12-16
US10442776B2 (en) 2019-10-15
US10494352B2 (en) 2019-12-03
US20190062288A1 (en) 2019-02-28
WO2016126721A1 (en) 2016-08-11
EA036711B1 (ru) 2020-12-10
US20200002298A1 (en) 2020-01-02
CN107873023B (zh) 2021-07-23
US10450284B2 (en) 2019-10-22
US20160222022A1 (en) 2016-08-04
US10450283B2 (en) 2019-10-22
AU2020257136A1 (en) 2020-11-19
US20190119229A1 (en) 2019-04-25
MX392538B (es) 2025-03-24
US10464910B2 (en) 2019-11-05
US20190112279A1 (en) 2019-04-18
EP3253747A1 (en) 2017-12-13
TWI712591B (zh) 2020-12-11
EP3292116A1 (en) 2018-03-14
JP6668362B2 (ja) 2020-03-18
EP3292116B1 (en) 2021-10-20
US20190112280A1 (en) 2019-04-18
ES2903523T3 (es) 2022-04-04
US11274085B2 (en) 2022-03-15
TW201636333A (zh) 2016-10-16
US20190112281A1 (en) 2019-04-18
US10829461B2 (en) 2020-11-10
TW202110813A (zh) 2021-03-16
IL279830B (en) 2022-08-01
US20160222028A1 (en) 2016-08-04
IL280856A (en) 2021-04-29
HK1253322A1 (zh) 2019-06-14
US10822316B2 (en) 2020-11-03
SG10202100916PA (en) 2021-02-25
ECSP17055491A (es) 2017-11-30
US12264137B2 (en) 2025-04-01
CA2975605A1 (en) 2016-08-11
AU2020260523A1 (en) 2020-11-26
HK1251550A1 (zh) 2019-02-01
HUE057623T2 (hu) 2022-05-28
TWI697486B (zh) 2020-07-01
US20190119227A1 (en) 2019-04-25
EP3253747B1 (en) 2019-11-27
EA201792673A1 (ru) 2018-04-30
US20190016693A1 (en) 2019-01-17
US20190127339A1 (en) 2019-05-02
US20210009539A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
IL280856A (en) 3-Alkyl-4-amino-[0,5,4] bicyclic hydroxamic acids as HDAC inhibitors
IL282103A (en) Furinones as ubiquitin-specific protease 1 inhibitors
HK1259073A1 (zh) 作為己酮糖激酶抑制劑的被取代的3-氮雜雙環[3‧1‧0]己烷
HK1245266A1 (zh) 作為usp30抑制劑的1-氰基吡咯烷化合物
HK1248222A1 (zh) 噻吩並嘧啶酮作為泛素特異性蛋白酶7抑制劑
EP3303324A4 (en) Novel corrosion inhibitors
IL265138B (en) Dopamine-b-hydroxylase inhibitors that penetrate the blood-brain barrier
EP3139918A4 (en) Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
EP3153582A4 (en) Improved nitrile hydratase
IL255024A0 (en) Hydroxamic acids and their uses
GB201616201D0 (en) Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors
GB201521588D0 (en) Fft 1
GB201520946D0 (en) Active tagging